Pharming Group Price to Free Cash Flow Ratio 2013-2024 | PHGUF

Pharming Group price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as

Pharming Group Price to Free Cash Flow Ratio 2013-2024 | PHGUF

Pharming Group price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$153.4B
Gilead Sciences (GILD)$121.1B
Bristol Myers Squibb (BMY)$119.6B
Vertex Pharmaceuticals (VRTX)$118.9B
CSL (CSLLY)$83.5B
Regeneron Pharmaceuticals (REGN)$74B
GSK (GSK)$73.1B
Argenex SE (ARGX)$39.8B
Alnylam Pharmaceuticals (ALNY)$35B
BioNTech SE (BNTX)$29.7B
BeiGene (ONC)$22B
Illumina (ILMN)$21.1B
Biogen (BIIB)$21B
Moderna (MRNA)$15.2B
Incyte (INCY)$14.3B
Insmed (INSM)$13.7B
Intra-Cellular Therapies (ITCI)$13.5B
Genmab (GNMSF)$13B
Genmab (GMAB)$13B
BioMarin Pharmaceutical (BMRN)$12.1B
Bio-Techne Corp (TECH)$11.7B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Exact Sciences (EXAS)$10.4B
Bio-Rad Laboratories (BIO.B)$10B
QIAGEN (QGEN)$9.9B
Exelixis (EXEL)$9.5B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B